Products

What will AGI do for Bemegride?

This classification denotes a cns stimulant with the molecular formula C8H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 57DQA39DO2, chemically known as 3,3-methylethylilotarimide but generally known as bemegride, which bears US NIH Compound Identifier 2310. Bemegride most often comes in base or methyl forms. European Medicines Agency schedules Bemegride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05691MIG. The term BEMEGRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules bemegride in its Anatomical Therapeutic Chemical (ATC) Classification. BEMEGRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bemegride under HS 29251995 and SITC 51482. As of Q4 2014, BEMEGRIDE remains the US FDA Preferred Term for this commodity. Bemegride bears US NLM identifiers UMLS ID C0004960 and NCI Concept Code C76617. SMILES: O=C1NC(=O)CC(C1)(CC)C.

How AGI delivers it

Four ways AGI delivers for Bemegride

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Bemegride, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Bemegride, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Bemegride connects

measured by

  • Active Ingredient Potencymodel
  • Compound Puritymodel
  • Melting Pointmodel
  • Residual Solventmodel